SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NexStar Pharm(NXTR)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John Veltheer who wrote (303)10/22/1998 7:27:00 PM
From: Steven Yang   of 328
 
NXTR investors:

NXTR reported its 98Q3 earning this morning. I am glad to note that the product sale has continued to grow in 98Q3 while the expenses are basically ketp flat. On the operation basis, NXTR lost about $1.1M, or (-0.04) per share. With such a small loss, NXTR would become profittable even with a small uptick in the sale.

According to the CC, NXTR is expected to grow its direct sale by 10-15% for the next year due to the lable expansion and the product sale in new territories, France in particular. It expects a higher growth rate in the US. A total revenue growth rate of 15% or higher is expected for 1999 when both the US market and the international market are combined.

The company management also mentioned that the preliminary results from the Phase II trial of MK is good. This is a very positive news for NXTR, since MK market is a lot larger than that of AB,

If the management's word can be believed, NXTR is very likely to be profittable for the next quarter, even without the proposed spin off.

Steven
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News